Bioplatforms Australia (BPA) and the Australian Cardiovascular Alliance are excited to announce an important new scheme open to CVD research teams across the country who are working in the ACvA flagships of big data, precision medicine and drug discovery and translation.
The ACvA leadership warmly welcomes this partnership with BPA.
BPA was established through the National Research Infrastructure Scheme (NCRIS) and currently manages a national network of ‘omics research infrastructure providers and the bioinformatics capacity needed to support these activities.
Biomolecular science is fundamental to scientific discovery. Genomics facilitates biomarker discovery, novel genetic testing and QC of biological products, proteomics, the targets for diagnostic and therapeutic intervention and metabolomics for rapid system monitoring and evaluation. Collectively, Bioplatforms Australia provides the capability to support all aspects of product development, production, QC and market performance.
The BPA/ACvA partnership will support pilot discovery work to assist with national collaborative programs using state-of-the-art technology platforms by providing access to BPA’s facilities.
The Research Catalyst Grants Program will provide “vouchers” of between $10,000 and $50,000 for access to “omics” technologies in the Bioplatforms Australia network of facilities.
Applications open on 4 May 2020. Please click HERE For further details and how to apply.